The drugmaker hopes to submit this data as part of a new drug application with the FDA later this year.
Although the FDA has already approved the regimen in this indication after seeing its impact on progression-free survival, the latest data speaks to its impact on survival.
As labs implement TMB workflows in-house, studies are showing that its is possible to validate assays with cutoff points remaining stable across complex clinical cohorts and in different drug contexts.
The study failed to show Opdivo plus chemoradiation significantly improves PFS compared to standard of care in MGMT-methylated glioblastoma.
The companies will use their respective technologies to identify inhibitors of cancer-associated gene targets and optimize their use as therapeutics.
The drugmaker will present data from the Impower110 trial at an upcoming meeting and submit the data to regulatory authorities.